JP2010530432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530432A5 JP2010530432A5 JP2010513267A JP2010513267A JP2010530432A5 JP 2010530432 A5 JP2010530432 A5 JP 2010530432A5 JP 2010513267 A JP2010513267 A JP 2010513267A JP 2010513267 A JP2010513267 A JP 2010513267A JP 2010530432 A5 JP2010530432 A5 JP 2010530432A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- phenyl
- fluorophenyl
- pyridyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 28
- -1 difluorophenylmethylthiazolyl Chemical group 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 102000011990 Sirtuin Human genes 0.000 claims 4
- 108050002485 Sirtuin Proteins 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 230000003381 solubilizing effect Effects 0.000 claims 4
- 125000001207 fluorophenyl group Chemical group 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 125000000068 chlorophenyl group Chemical group 0.000 claims 2
- 125000004212 difluorophenyl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 101000654472 Homo sapiens NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 102100030710 NAD-dependent protein deacetylase sirtuin-3, mitochondrial Human genes 0.000 claims 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 1
- 108091005770 SIRT3 Proteins 0.000 claims 1
- 102000000344 Sirtuin 1 Human genes 0.000 claims 1
- 108010041191 Sirtuin 1 Proteins 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000002921 anti-spasmodic effect Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000006196 deacetylation Effects 0.000 claims 1
- 238000003381 deacetylation reaction Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 102000056482 human SIRT1 Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000024883 vasodilation Effects 0.000 claims 1
- LVDUUIXBZXBALU-UHFFFAOYSA-N CC(C)NCc1cnc2[s]c(-c(cccc3)c3NC(c3cc(-c4ccccc4)cnc3)=O)nc2c1 Chemical compound CC(C)NCc1cnc2[s]c(-c(cccc3)c3NC(c3cc(-c4ccccc4)cnc3)=O)nc2c1 LVDUUIXBZXBALU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93663607P | 2007-06-20 | 2007-06-20 | |
| US60/936,636 | 2007-06-20 | ||
| PCT/US2008/007776 WO2008156869A2 (en) | 2007-06-20 | 2008-06-20 | Sirtuin modulating thiazolopyridine compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010530432A JP2010530432A (ja) | 2010-09-09 |
| JP2010530432A5 true JP2010530432A5 (enExample) | 2011-08-04 |
| JP5498940B2 JP5498940B2 (ja) | 2014-05-21 |
Family
ID=39798234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010513267A Expired - Fee Related JP5498940B2 (ja) | 2007-06-20 | 2008-06-20 | サーチュイン調節性チアゾロピリジン化合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7893086B2 (enExample) |
| EP (1) | EP2170905A2 (enExample) |
| JP (1) | JP5498940B2 (enExample) |
| KR (1) | KR20100051048A (enExample) |
| CN (2) | CN103833775A (enExample) |
| AR (1) | AR067107A1 (enExample) |
| AU (1) | AU2008266749C1 (enExample) |
| BR (1) | BRPI0813651A2 (enExample) |
| CA (1) | CA2691733A1 (enExample) |
| CL (1) | CL2008001822A1 (enExample) |
| CO (1) | CO6251248A2 (enExample) |
| CR (1) | CR11232A (enExample) |
| DO (1) | DOP2009000284A (enExample) |
| EA (1) | EA018922B1 (enExample) |
| IL (1) | IL202730A0 (enExample) |
| MA (1) | MA31506B1 (enExample) |
| MX (1) | MX2009013977A (enExample) |
| NZ (1) | NZ581990A (enExample) |
| PE (1) | PE20090694A1 (enExample) |
| TW (1) | TW200916472A (enExample) |
| UY (1) | UY31169A1 (enExample) |
| WO (1) | WO2008156869A2 (enExample) |
| ZA (1) | ZA200908883B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007019345A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Imidazopyridine derivatives as sirtuin modulating agents |
| WO2007041643A1 (en) * | 2005-10-03 | 2007-04-12 | University Of Tennessee Research Foundation | Dietary calcium for reducing the production of reactive oxygen species |
| TW200916472A (en) * | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| CL2008001821A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
| CL2008001933A1 (es) * | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| CN101801958B (zh) * | 2007-07-19 | 2014-01-29 | 默沙东公司 | 作为蛋白质激酶抑制剂的杂环酰胺化合物 |
| MX2010005186A (es) * | 2007-11-08 | 2010-05-27 | Sirtris Pharmaceuticals Inc | Tiazolopiridinas solubilizadas. |
| CA2723135A1 (en) | 2008-05-01 | 2009-11-05 | Sirtris Pharmaceuticals, Inc. | Quenolines and related analogs as sirtuin modulators |
| US8846947B2 (en) * | 2008-07-03 | 2014-09-30 | Glaxosmithkline Llc | Benzimidazoles and related analogs as sirtuin modulators |
| CA2738809C (en) | 2008-09-29 | 2015-11-24 | Sirtris Pharmaceuticals, Inc. | Quinazolinone, quinolone and related analogs as sirtuin modulators |
| CN102369014A (zh) | 2008-12-08 | 2012-03-07 | 西北大学 | 调节hsf-i的方法 |
| CN102388054B (zh) | 2008-12-19 | 2015-03-04 | 西特里斯药业公司 | 噻唑并吡啶沉默调节蛋白调节剂的化合物 |
| KR20120092141A (ko) | 2009-10-29 | 2012-08-20 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 비시클릭 피리딘 및 유사체 |
| AU2011232347B2 (en) * | 2010-03-24 | 2015-08-06 | Musc Foundation For Research Development | Compositions and methods for the treatment of degenerative diseases |
| EP2558589A4 (en) * | 2010-04-15 | 2014-01-01 | Glaxosmithkline Llc | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS FOR THIS |
| CN102933711B (zh) * | 2010-05-03 | 2018-01-02 | 库尔纳公司 | 通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病 |
| EP2423214A1 (en) | 2010-08-13 | 2012-02-29 | Solvay SA | Light emitting materials for Electronics |
| TW201223956A (en) | 2010-08-13 | 2012-06-16 | Solvay | Light emitting materials for electronics |
| KR20120047341A (ko) * | 2010-10-21 | 2012-05-14 | 경상대학교산학협력단 | 니코틴아미드를 유효성분으로 포함하는 알킬화 약물-유도성 신경퇴행의 예방 또는 치료용 조성물 |
| JP2014505705A (ja) | 2011-02-02 | 2014-03-06 | ザ トラスティーズ オブ プリンストン ユニヴァシティ | ウイルス生成モジュレーターとしてのサーチュインモジュレーター |
| KR101329524B1 (ko) | 2011-05-23 | 2013-11-13 | 연세대학교 산학협력단 | 미분화 전능성 줄기세포의 선택적 세포사멸 방법 |
| RU2631597C2 (ru) | 2011-07-15 | 2017-09-25 | Нусерт Сайенсиз, Инк. | Композиции и способы модулирования метаболических путей |
| CN104010651A (zh) | 2011-09-07 | 2014-08-27 | 康奈尔大学 | 通过靶向Sirt5治疗癌症的方法 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
| AU2013344753B2 (en) | 2012-11-13 | 2018-09-27 | Nusirt Sciences, Inc. | Compositions and methods for increasing energy metabolism |
| SG11201507046UA (en) | 2013-03-15 | 2015-10-29 | Nusirt Sciences Inc | Leucine and nicotinic acid reduces lipid levels |
| MX2016011063A (es) | 2014-02-27 | 2016-11-30 | Nusirt Sciences Inc | Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica. |
| WO2015143654A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| WO2015186068A1 (en) | 2014-06-02 | 2015-12-10 | Glaxosmithkline Intellectual Property (No.2) Limited | Preparation and use of crystalline beta-d-nicotinamide riboside |
| RU2016149767A (ru) | 2014-06-06 | 2018-07-16 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Аналоги никотинамидрибозида и фармацевтические композиции и их применение |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| CN107496410A (zh) * | 2017-09-21 | 2017-12-22 | 上海华堇生物技术有限责任公司 | 洋槐黄素的药物用途 |
| JP2021501198A (ja) * | 2017-10-27 | 2021-01-14 | トランスフュージョン ヘルス，リミティド ライアビリティ カンパニー | フルオレンの誘導体を用いて造血幹細胞を増殖する組成物および方法 |
| KR20200133747A (ko) | 2018-02-20 | 2020-11-30 | 인사이트 코포레이션 | 암을 치료하기 위한 hpk1 억제제로서의 n-(페닐)-2-(페닐)피리미딘-4-카복스아미드 유도체 및 관련 화합물 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| WO2021026180A1 (en) | 2019-08-06 | 2021-02-11 | Incyte Corporation | Solid forms of an hpk1 inhibitor |
| WO2024005905A2 (en) * | 2022-04-29 | 2024-01-04 | The Regents Of The University Of Michigan | Small molecule sirtuin inhibitors and uses thereof |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3164603A (en) | 1965-01-05 | xnhcox | ||
| DE1108698B (de) | 1959-09-03 | 1961-06-15 | Hoechst Ag | Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen |
| FR1439129A (fr) | 1965-04-02 | 1966-05-20 | Chimetron | Nouveaux sulfonylbenzimidazoles |
| FR1476529A (fr) | 1965-04-24 | 1967-04-14 | Chimetron Sarl | Nouveaux dérivés benzimidazole-sulfoniques et sulfamides correspondants |
| FR1450625A (fr) | 1965-06-18 | 1966-06-24 | Chimetron Sarl | Sulfonamidothiazolyl-2 benzimidazoles |
| US3503929A (en) | 1965-10-21 | 1970-03-31 | Minnesota Mining & Mfg | Polyimidazoquinazolines and polyamidobenzimidazoles |
| US3517007A (en) | 1968-04-05 | 1970-06-23 | American Home Prod | 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds |
| US3928228A (en) | 1969-04-28 | 1975-12-23 | Sterling Drug Inc | 4,4{40 -Stilbenebis-pyridooxazoles and related optical brighteners and polymeric compositions brightened thereby |
| US3712888A (en) | 1970-12-14 | 1973-01-23 | American Cyanamid Co | Bis-pyridoxazole-stilbene derivatives for optical brightening |
| CA1006165A (en) | 1971-04-06 | 1977-03-01 | Eastman Kodak Company | Ballasted color photographic couplers |
| AR208500A1 (es) | 1972-06-14 | 1977-02-15 | Merck & Co Inc | Procedimiento para la preparacion de derivados de oxazolo(4,5-b)-piridinas |
| US4038396A (en) | 1975-02-24 | 1977-07-26 | Merck & Co., Inc. | Anti-inflammatory oxazole[4,5-b]pyridines |
| PL96241B1 (pl) | 1975-06-30 | 1977-12-31 | Sposob wytwarzania 2-/2-podstawionych-4-tiazolilo/-benzimidazoli | |
| JPS6040016B2 (ja) | 1977-08-31 | 1985-09-09 | コニカ株式会社 | マゼンタ色素画像の形成方法 |
| US4471040A (en) | 1980-09-10 | 1984-09-11 | Canon Kabushiki Kaisha | Electrophotographic disazo photosensitive member |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4939133A (en) | 1985-10-01 | 1990-07-03 | Warner-Lambert Company | N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade |
| DE3807084A1 (de) | 1988-03-04 | 1989-09-14 | Knoll Ag | Neue benzimidazo(1,2-c)chinazoline, ihre herstellung und verwendung |
| JPH04190232A (ja) | 1990-11-26 | 1992-07-08 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| JPH04191736A (ja) | 1990-11-27 | 1992-07-10 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
| JPH06247969A (ja) | 1992-12-28 | 1994-09-06 | Takeda Chem Ind Ltd | 縮合複素環化合物及びそれを含む農園芸用殺虫剤 |
| WO1995032960A1 (en) | 1994-05-31 | 1995-12-07 | Mitsui Toatsu Chemicals, Incorporated | Benzimidazole derivative |
| US5821258A (en) | 1994-12-27 | 1998-10-13 | Mitsui Chemicals, Inc. | Phenylbenzimidazole derivatives |
| AUPN449295A0 (en) | 1995-07-28 | 1995-08-24 | Inner And Eastern Health Care Network, The | Radioprotectors |
| AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US5808087A (en) | 1995-11-29 | 1998-09-15 | Mitsui Chemicals, Inc. | Sulfonium salts of pyrrolylbenzimidazoles |
| WO1999033824A1 (en) | 1997-12-31 | 1999-07-08 | Rutgers, The State University Of New Jersey | Heterocyclic topoisomerase poisons |
| JP4412521B2 (ja) | 1998-03-31 | 2010-02-10 | 塩野義製薬株式会社 | ｓＰＬＡ２阻害作用を有するピロロ［１，２−ａ］ピラジン誘導体 |
| YU13701A (sh) | 1998-08-20 | 2005-06-10 | Agouron Pharmaceuticals Inc. | GnRH SREDSTVA KOJA NISU PEPTIDI, POSTUPCI I INTERMEDIJERI ZA NJIHOVO DOBIJANJE |
| US6653309B1 (en) | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
| EP1177188B1 (en) | 1999-05-12 | 2005-10-12 | Ortho-McNeil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
| GB2351081A (en) | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Pharmaceutically active imidazoline compounds and analogues thereof |
| ATE301651T1 (de) | 1999-06-23 | 2005-08-15 | Aventis Pharma Gmbh | Substituierte benzimidazole |
| AU7314200A (en) | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
| US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| WO2001090067A1 (en) | 2000-05-22 | 2001-11-29 | Takeda Chemical Industries, Ltd. | Tyrosine phosphatase inhibitors |
| JP2004503553A (ja) | 2000-06-14 | 2004-02-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | ６，５−縮合二環式複素環 |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| JP2002161084A (ja) | 2000-11-28 | 2002-06-04 | Sumitomo Pharmaceut Co Ltd | 複素環誘導体 |
| US20040010033A1 (en) | 2001-02-20 | 2004-01-15 | Pfizer Inc. | Non-peptide GnRH agents, methods and intermediates for their preparation |
| WO2002066454A1 (fr) | 2001-02-21 | 2002-08-29 | Sankyo Company, Limited | Derives de chromene |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| RU2003131693A (ru) | 2001-03-28 | 2005-05-10 | Бристол-Маерс Сквибб Компани (Us) | Новые ингибиторы тирозин киназ |
| US6716866B2 (en) | 2001-06-13 | 2004-04-06 | Genesoft Pharmaceuticals, Inc. | Aryl-benzimidazole compounds having antiinfective activity |
| WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| AU2002327390B2 (en) | 2001-07-27 | 2008-06-26 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| EP1572072A4 (en) | 2001-09-13 | 2009-04-01 | Genesoft Inc | PROCESS FOR TREATING INFECTIONS WITH PHARMACORESISTANT BACTERIA |
| US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
| US7622479B2 (en) | 2001-11-26 | 2009-11-24 | Takeda Pharmaceutical Company Limited | Bicyclic derivative, its production and use |
| WO2003048140A1 (en) | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
| CN1939307A (zh) | 2002-02-05 | 2007-04-04 | 安斯泰来制药有限公司 | 2,4,6－三氨基－1,3,5－三嗪衍生物 |
| ES2437391T3 (es) | 2002-02-06 | 2014-01-10 | Vertex Pharmaceuticals, Inc. | Compuestos de heteroarilo útiles como inhibidores de GSK-3 |
| GB0205256D0 (en) | 2002-03-06 | 2002-04-17 | Oxford Glycosciences Uk Ltd | Novel compounds |
| EP1487797B1 (en) | 2002-03-18 | 2009-05-27 | Merck Frosst Canada Ltd. | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors |
| CA2479338A1 (en) | 2002-03-20 | 2003-10-02 | Metabolex, Inc. | Substituted phenylacetic acids |
| TW200304820A (en) | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| JP4224979B2 (ja) | 2002-04-09 | 2009-02-18 | 大正製薬株式会社 | インターロイキン１２抑制剤 |
| JP4239463B2 (ja) | 2002-04-09 | 2009-03-18 | 大正製薬株式会社 | ３−トリフルオロメチルアニリド誘導体 |
| WO2003103669A1 (en) | 2002-04-18 | 2003-12-18 | Schering Corporation | 1-(4-piperidinyl) benzimidazolones as histamine h3 antagonists |
| JP2003313176A (ja) | 2002-04-24 | 2003-11-06 | Sankyo Co Ltd | アミノアゾール誘導体 |
| JPWO2003103648A1 (ja) | 2002-06-05 | 2005-10-06 | 株式会社医薬分子設計研究所 | 糖尿病治療薬 |
| KR20050025345A (ko) | 2002-07-12 | 2005-03-14 | 아벤티스 파마 도이칠란트 게엠베하 | 헤테로사이클릭으로 치환된 벤조일우레아, 이들의제조방법 및 약제로서 이의 용도 |
| ES2385378T3 (es) | 2002-07-24 | 2012-07-24 | Dermira (Canada), Inc. | Derivados de pirazolilbenzotiazol y su uso como agentes terapéuticos |
| SE0202429D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel Compounds |
| DE10237722A1 (de) | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
| JP2004075614A (ja) | 2002-08-20 | 2004-03-11 | Sankyo Co Ltd | クロメン誘導体を含有する医薬 |
| TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| EP1562605A4 (en) | 2002-10-08 | 2006-07-12 | Massachusetts Inst Technology | COMPOUNDS FOR MODULATING CHOLESTER INTRANSPORT |
| JP2006504725A (ja) | 2002-10-09 | 2006-02-09 | ファイザー・プロダクツ・インク | 神経変性障害治療用ピラゾール化合物 |
| WO2004033666A2 (en) | 2002-10-11 | 2004-04-22 | Board Of Regents, The University Of Texas System | Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases |
| EP1562931A2 (en) | 2002-10-25 | 2005-08-17 | Genesoft Pharmaceuticals, Inc. | Anti-infective biaryl compounds |
| JP2006513159A (ja) | 2002-11-01 | 2006-04-20 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体モジュレーターとしてのカルボニルアミノ−ベンズイミダゾール誘導体 |
| AU2003302497A1 (en) | 2002-11-27 | 2004-06-23 | Ph. D. Edward M. Eddy | Glyceraldehyde 3-phosphate dehydrogenase-s(gapds), a glycolytic enzyme expressed only in male germ cells,is a target for male contraception |
| DE10300398A1 (de) | 2003-01-09 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von substituierten 2-Phenylbenzimidazolen als Arzneimittel |
| WO2004069160A2 (en) | 2003-01-28 | 2004-08-19 | Smithkline Beecham Corporation | Chemical compounds |
| AU2004212490B2 (en) | 2003-02-10 | 2008-05-15 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| DK2476667T3 (da) | 2003-02-26 | 2014-09-15 | Sugen Inc | Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer |
| CA2517720A1 (en) | 2003-03-11 | 2004-09-23 | Pfizer Products Inc. | Pyrazine compounds as transforming growth factor (tgf) inhibitors |
| EP1606266A4 (en) | 2003-03-21 | 2008-06-25 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| DE602004008304T2 (de) | 2003-09-12 | 2008-05-08 | 4 Aza Ip Nv | Pteridin-derivate zur behandlung von erkrankungen im zusammenhang mit tnf-alpha |
| GB2405793A (en) | 2003-09-12 | 2005-03-16 | 4 Aza Bioscience Nv | Pteridine derivatives for treating TNF-alpha related disorders |
| WO2005028484A1 (en) | 2003-09-19 | 2005-03-31 | F. Hoffmann-La Roche Ag | Thiazolopyridine derivatives as adenosine receptor ligands |
| JP4795634B2 (ja) | 2003-10-31 | 2011-10-19 | 出光興産株式会社 | 有機薄膜トランジスタ |
| JP2005162855A (ja) | 2003-12-02 | 2005-06-23 | Konica Minolta Holdings Inc | 着色組成物、インクジェット記録用インク、カラートナー、光記録媒体、感熱転写記録材料用インクシート、カラーフィルター、及び該インクジェット記録用インクを用いたインクジェット記録方法 |
| ATE473973T1 (de) | 2004-02-11 | 2010-07-15 | Basilea Pharmaceutica Ag | Substituierte benzimidazole und deren verwendung zur induktion von apoptose |
| WO2005100342A1 (en) * | 2004-03-26 | 2005-10-27 | Vertex Pharmaceuticals, Incorporated | Pyridine inhibitors of erk2 and uses thereof |
| DE102004021716A1 (de) | 2004-04-30 | 2005-12-01 | Grünenthal GmbH | Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen |
| TW200600492A (en) | 2004-05-18 | 2006-01-01 | Achillion Pharmaceuticals Inc | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
| RS53895B1 (sr) | 2004-06-24 | 2015-08-31 | Vertex Pharmaceuticals Incorporated | Modulatori atp-vezujućih kasetnih transportera |
| SG155222A1 (en) | 2004-08-13 | 2009-09-30 | Genentech Inc | Thiazole based inhibitors of atp-utilizing enzymes |
| DE102004039789A1 (de) * | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| EP1807074B1 (en) | 2004-11-03 | 2013-10-23 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| JP2008519850A (ja) | 2004-11-10 | 2008-06-12 | シンタ ファーマシューティカルズ コーポレーション | Ｉｌ−１２調節化合物 |
| US20100160324A1 (en) | 2004-12-30 | 2010-06-24 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| JP4635633B2 (ja) | 2005-02-04 | 2011-02-23 | 横浜ゴム株式会社 | 空気入りタイヤおよびその製造方法 |
| WO2006094236A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
| US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| WO2007019345A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Imidazopyridine derivatives as sirtuin modulating agents |
| US7935957B2 (en) * | 2005-08-12 | 2011-05-03 | Semiconductor Energy Laboratory Co., Ltd. | Memory device and a semiconductor device |
| JP4191736B2 (ja) | 2006-01-11 | 2008-12-03 | 日本電信電話株式会社 | 電界通信システム |
| AU2008221263B2 (en) | 2007-03-01 | 2012-02-23 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| CL2008001821A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
| US20100168084A1 (en) | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
-
2008
- 2008-06-19 TW TW097122810A patent/TW200916472A/zh unknown
- 2008-06-19 CL CL2008001822A patent/CL2008001822A1/es unknown
- 2008-06-20 KR KR1020107000400A patent/KR20100051048A/ko not_active Ceased
- 2008-06-20 JP JP2010513267A patent/JP5498940B2/ja not_active Expired - Fee Related
- 2008-06-20 CN CN201310744228.7A patent/CN103833775A/zh active Pending
- 2008-06-20 PE PE2008001058A patent/PE20090694A1/es not_active Application Discontinuation
- 2008-06-20 CN CN200880103654A patent/CN101801981A/zh active Pending
- 2008-06-20 BR BRPI0813651-3A2A patent/BRPI0813651A2/pt not_active IP Right Cessation
- 2008-06-20 AR ARP080102663A patent/AR067107A1/es not_active Application Discontinuation
- 2008-06-20 WO PCT/US2008/007776 patent/WO2008156869A2/en not_active Ceased
- 2008-06-20 EP EP08768700A patent/EP2170905A2/en not_active Withdrawn
- 2008-06-20 AU AU2008266749A patent/AU2008266749C1/en not_active Ceased
- 2008-06-20 UY UY31169A patent/UY31169A1/es not_active Application Discontinuation
- 2008-06-20 US US12/214,805 patent/US7893086B2/en not_active Expired - Fee Related
- 2008-06-20 MX MX2009013977A patent/MX2009013977A/es active IP Right Grant
- 2008-06-20 CA CA002691733A patent/CA2691733A1/en not_active Abandoned
- 2008-06-20 EA EA201070035A patent/EA018922B1/ru not_active IP Right Cessation
- 2008-06-20 NZ NZ581990A patent/NZ581990A/en not_active IP Right Cessation
-
2009
- 2009-12-11 DO DO2009000284A patent/DOP2009000284A/es unknown
- 2009-12-14 IL IL202730A patent/IL202730A0/en unknown
- 2009-12-14 ZA ZA200908883A patent/ZA200908883B/xx unknown
-
2010
- 2010-01-07 MA MA32482A patent/MA31506B1/fr unknown
- 2010-01-08 CO CO10001887A patent/CO6251248A2/es not_active Application Discontinuation
- 2010-01-20 CR CR11232A patent/CR11232A/es not_active Application Discontinuation
-
2011
- 2011-01-24 US US13/012,775 patent/US8268862B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010530432A5 (enExample) | ||
| JP2010530431A5 (enExample) | ||
| JP7262599B2 (ja) | タンパク質キナーゼ阻害活性を有する新規なピリド［３，４－ｄ］ピリミジン－８－オン誘導体およびこれを含む癌の予防、改善または治療用薬学組成物 | |
| TWI280127B (en) | Remedies for neurodegenerative diseases | |
| Côté et al. | Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses | |
| US4528291A (en) | 2-(4'-Pyridinyl)-thiazole compounds and their use in increasing cardiac contractility | |
| AU2018275277B2 (en) | Pharmaceutically acceptable salt of EGFR inhibitor, crystal form thereof, preparation method therefor and application thereof | |
| NZ594122A (en) | 2-Phenyl-N-(2-(6-(pyrrolidin-1-ylmethyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)thiazole-4-carboxamide derivatives | |
| US5721277A (en) | Compounds and methods for inhibiting hyper-proliferative cell growth | |
| CA2697077A1 (en) | 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors | |
| US20110112110A1 (en) | Antiproliferative compounds and therapeutic uses thereof | |
| WO2017101803A1 (zh) | 一种新型egfr和alk激酶的双重抑制剂 | |
| CN101584691A (zh) | 影响葡糖激酶的化合物 | |
| Wrobleski et al. | Structural comparison of p38 inhibitor-protein complexes: a review of recent p38 inhibitors having unique binding interactions | |
| TW200817350A (en) | Biaryloxymethylarenecarboxylic acids | |
| EP1578745A1 (en) | Benzofuran derivates, process for their preparation and intermediates thereof | |
| SI9520081A (en) | Use of thiazoles and thiadiazoles compounds as d3 dopamine receptor ligands. | |
| KR20140016889A (ko) | 디아릴아세틸렌 히드라지드 함유 티로신 키나제 억제제 | |
| JP5860865B2 (ja) | 代謝型グルタミン酸受容体の調節剤としてのニコチン酸誘導体 | |
| TW200410675A (en) | An NF-κB activation inhibitor | |
| WO2020052627A1 (zh) | 取代的吡咯并嘧啶类cdk抑制剂的盐及其结晶和用途 | |
| KR101572280B1 (ko) | 파킨슨병의 치료를 위한 대사성 글루타메이트 수용체 조절제 | |
| EA039144B1 (ru) | Новые гетероариламидные производные как селективные ингибиторы гистондеацетилаз 1 и/или 2 (hdac1-2) | |
| CN101575333B (zh) | 一种喹唑啉衍生物及其医药用途 | |
| WO2017114383A1 (zh) | 一类新型的egfr野生型和突变型的激酶抑制剂 |